On May 19, 2021 NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, reported that clinical data from its Phase 1/2 dose escalation study of NEXI-001 will be presented in a poster session at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2021 Annual Meeting being held virtually from June 4 – June 8, 2021 (Press release, NexImmune, MAY 19, 2021, View Source [SID1234580370]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Presentation:
Title: Preliminary Analysis of a Phase 1/2 Study of NEXI-001 Donor-Derived Multi-Antigen-Specific CD8+ T Cell Treatment of Relapsed Acute Myeloid Leukemia (AML) After Allogeneic Hematopoietic Cell Transplantation (HCT)
Abstract #: 2538
Session Title: Poster Session: Developmental Therapeutics – Immunotherapy
Authors: Monzr M. Al Malki, MD1, Sumithira Vasu, MBBS2, Dipenkumar Modi, MD3, Miguel-Angel Perales, MD4, Megan Nelson, RN, BSN5, Donna Bui1, Vineetha Edavana, PhD6, Sojung Kim, PhD6, Lauren Suarez, PhD6, Mathias Oelke, PhD6, Robert D. Knight, MD6, and Juan C. Varela, MD, PhD5
(1) Hematology/Hematopoietic Cell Transplant, City of Hope National Medical Center, Duarte, CA, (2)Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, (3)Division of Oncology, Karmanos Cancer Center/ Wayne State University, Detroit, MI, (4)Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, (5)Advent Health Blood and Marrow Transplant Program, Orlando, FL, (6)NexImmune Inc, Gaithersburg, MD.